Zymeworks Inc (ZYME)

$18.52 +0.02 (0.11%)
Market Cap 1.39B
Revenue (ttm) 76.30M
Net Income (ttm) -122.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.81%
Debt to Equity Ratio 0.00
Volume 824,800
Avg Vol 817,204
Day's Range N/A - N/A
Shares Out 74.84M
Stochastic %K 60%
Beta 1.48
Analysts Strong Sell
Price Target $24.82

Company Profile

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform in...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 274 8744
Address:
108 Patriot Drive, Suite A, Middletown, United States
HedgeAlerts
HedgeAlerts Nov. 16 at 11:10 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ZYME $17.50 Put · NOV 21, 2025 Exp Entry Price: $0.54 - $4.90 Exit Price Target: $1.25 Profit Margin: +132% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 12:01 PM
💎 LiquidTheta® Live Actionable Trade Asset: $ZYME Contracts: $ZYME April 17, 2026 $20 Calls Scale in: $5.58- $6.82 Scale out: $21.70-$37.20 Profit Potential : 298% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 11:13 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ZYME $17.50 Put · NOV 21, 2025 Exp Entry Price: $0.54 - $4.90 Exit Price Target: $1.25 Profit Margin: +132% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:56 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ZYME $17.50 Put · NOV 21, 2025 Exp Entry Price: $0.54 - $4.90 Exit Price Target: $0.87 Profit Margin: +62% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 8:16 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ZYME $17.50 Put · NOV 21, 2025 Exp Entry Price: $0.54 - $2.00 Exit Price Target: $1.15 Profit Margin: +113% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
twitofstock
twitofstock Nov. 13 at 2:54 PM
$ZYME new trial results 1b/2 first line metastatic breast cancer: response rate 90.9%, median progression-free survival 22.1 months and median overall survival 36.9 months https://pubmed.ncbi.nlm.nih.gov/41202501/
0 · Reply
twitofstock
twitofstock Nov. 12 at 6:45 PM
$ZYME what's with the massive volume for deep out of the money put options, dec19 ?
1 · Reply
KirRoyalTrader
KirRoyalTrader Nov. 11 at 11:52 PM
$ZYME Massive moves over the last two days on strong volume, and it’s still up another 3% after hours (New 3 years high). The $17 base is now history.
0 · Reply
NorthShoreTrader2021
NorthShoreTrader2021 Nov. 11 at 11:25 PM
$ZYME Can we see $59 again or even higher over $100 ?
1 · Reply
mostbullish
mostbullish Nov. 11 at 9:43 PM
$ZYME there is a reason that Ecor1 have been buying up so they own 35% and now dominates the BoD. They fonna block any foolish stuff and make sure Zyme is sold as a platform play tagher then a one reick pony. Might have to wait for ZW ph2 but then we are looking at 3x-5x from here. Meantime Zhme is gonna settle in the 20s
2 · Reply
Latest News on ZYME
Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 12:06 AM EST - 10 days ago

Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 10 days ago

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Zymeworks Announces Participation in Upcoming Investor Conferences

Oct 28, 2025, 6:00 AM EDT - 19 days ago

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript

Oct 23, 2025, 9:47 PM EDT - 24 days ago

Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Oct 23, 2025, 12:30 PM EDT - 24 days ago

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Oct 16, 2025, 6:00 AM EDT - 4 weeks ago

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Oct 13, 2025, 4:00 PM EDT - 4 weeks ago

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Oct 9, 2025, 8:30 AM EDT - 5 weeks ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

INM

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Oct 9, 2025, 6:00 AM EDT - 5 weeks ago

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On

Sep 2, 2025, 6:09 PM EDT - 2 months ago

Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Sep 2, 2025, 12:30 PM EDT - 2 months ago

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Zymeworks halts development of cancer drug after trial setback

Sep 2, 2025, 6:18 AM EDT - 2 months ago

Zymeworks halts development of cancer drug after trial setback

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Sep 2, 2025, 6:00 AM EDT - 2 months ago

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Aug 11, 2025, 6:00 AM EDT - 3 months ago

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 4:33 PM EDT - 3 months ago

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 3 months ago

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Jul 28, 2025, 6:00 AM EDT - 3 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Jul 17, 2025, 6:00 AM EDT - 4 months ago

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

Jun 12, 2025, 4:34 PM EDT - 5 months ago

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 30, 2025, 6:00 AM EDT - 6 months ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 22, 2025, 5:00 PM EDT - 6 months ago

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 19, 2025, 4:15 PM EDT - 6 months ago

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:00 PM EDT - 6 months ago

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 6 months ago

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline

Apr 28, 2025, 5:33 PM EDT - 7 months ago

Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline

Zymeworks: Poised For Growth With Platform Validation

Apr 28, 2025, 10:48 AM EDT - 7 months ago

Zymeworks: Poised For Growth With Platform Validation

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Apr 25, 2025, 1:00 PM EDT - 7 months ago

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Apr 21, 2025, 6:00 AM EDT - 7 months ago

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 17, 2025, 6:00 AM EDT - 7 months ago

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 8 months ago

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Mar 6, 2025, 1:18 PM EST - 9 months ago

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 8:43 PM EST - 9 months ago

Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 4:05 PM EST - 9 months ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Feb 26, 2025, 6:00 AM EST - 9 months ago

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Feb 18, 2025, 6:00 AM EST - 9 months ago

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Feb 13, 2025, 6:00 AM EST - 9 months ago

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 10 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT JAZZ ONC XBI

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Jan 8, 2025, 4:05 PM EST - 11 months ago

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Dec 19, 2024, 9:00 AM EST - 11 months ago

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Nov 21, 2024, 6:00 AM EST - 1 year ago

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Nov 5, 2024, 6:00 AM EST - 1 year ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Nov 4, 2024, 4:28 AM EST - 1 year ago

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 10:05 PM EDT - 1 year ago

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Oct 25, 2024, 6:00 AM EDT - 1 year ago

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Oct 21, 2024, 6:00 AM EDT - 1 year ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

Oct 10, 2024, 6:30 AM EDT - 1 year ago

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27, 2024, 2:47 PM EDT - 1 year ago

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Sep 18, 2024, 6:00 AM EDT - 1 year ago

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

Sep 3, 2024, 4:30 PM EDT - 1 year ago

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:58 PM EDT - 1 year ago

Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript

HedgeAlerts
HedgeAlerts Nov. 16 at 11:10 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ZYME $17.50 Put · NOV 21, 2025 Exp Entry Price: $0.54 - $4.90 Exit Price Target: $1.25 Profit Margin: +132% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 12:01 PM
💎 LiquidTheta® Live Actionable Trade Asset: $ZYME Contracts: $ZYME April 17, 2026 $20 Calls Scale in: $5.58- $6.82 Scale out: $21.70-$37.20 Profit Potential : 298% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 11:13 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ZYME $17.50 Put · NOV 21, 2025 Exp Entry Price: $0.54 - $4.90 Exit Price Target: $1.25 Profit Margin: +132% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:56 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ZYME $17.50 Put · NOV 21, 2025 Exp Entry Price: $0.54 - $4.90 Exit Price Target: $0.87 Profit Margin: +62% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 8:16 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ZYME $17.50 Put · NOV 21, 2025 Exp Entry Price: $0.54 - $2.00 Exit Price Target: $1.15 Profit Margin: +113% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
twitofstock
twitofstock Nov. 13 at 2:54 PM
$ZYME new trial results 1b/2 first line metastatic breast cancer: response rate 90.9%, median progression-free survival 22.1 months and median overall survival 36.9 months https://pubmed.ncbi.nlm.nih.gov/41202501/
0 · Reply
twitofstock
twitofstock Nov. 12 at 6:45 PM
$ZYME what's with the massive volume for deep out of the money put options, dec19 ?
1 · Reply
KirRoyalTrader
KirRoyalTrader Nov. 11 at 11:52 PM
$ZYME Massive moves over the last two days on strong volume, and it’s still up another 3% after hours (New 3 years high). The $17 base is now history.
0 · Reply
NorthShoreTrader2021
NorthShoreTrader2021 Nov. 11 at 11:25 PM
$ZYME Can we see $59 again or even higher over $100 ?
1 · Reply
mostbullish
mostbullish Nov. 11 at 9:43 PM
$ZYME there is a reason that Ecor1 have been buying up so they own 35% and now dominates the BoD. They fonna block any foolish stuff and make sure Zyme is sold as a platform play tagher then a one reick pony. Might have to wait for ZW ph2 but then we are looking at 3x-5x from here. Meantime Zhme is gonna settle in the 20s
2 · Reply
mostbullish
mostbullish Nov. 11 at 9:39 PM
$ZYME some morons were claiming that including all 920 pts in the read out coming next month was a bad thing. Stock drop friday but ups ! over the weekend everyone figured out this was actually a bullish thing.
0 · Reply
NyseDayTrader
NyseDayTrader Nov. 11 at 9:36 PM
$ZYME man! I was heavy involved in this years ago when the okd CEO(Tehrani) was a bogus hype machine. Good for you guys. Looks strong
2 · Reply
kiwitc2000
kiwitc2000 Nov. 11 at 9:03 PM
$ZYME Would you look at that? Not sure what happened but?
0 · Reply
Lol_at_ur_bags
Lol_at_ur_bags Nov. 11 at 8:24 PM
$ZYME
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Nov. 11 at 7:17 PM
$ZYME 💪
0 · Reply
Lol_at_ur_bags
Lol_at_ur_bags Nov. 11 at 5:35 PM
$ZYME
0 · Reply
NoBSPls
NoBSPls Nov. 10 at 8:56 PM
$ZYME Up almost 10% and nobody posts??
2 · Reply
maplelakeduckslayer
maplelakeduckslayer Nov. 10 at 4:01 PM
$ZYME Again...everyone only focused on Jazz and Zani. Theres way more to this company even outside their wholly owned pipeline
1 · Reply
Iightning
Iightning Nov. 10 at 5:47 AM
1ightning® Options Trade Alert (Actionable) | Buy $ZYME Nov 21 $20 Call | Enter: $2.50 Exit: $4.23 | Profit: 69.11% ROI | https://1ightning.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 9 at 12:34 PM
💎 LiquidTheta® Live Actionable Trade Asset: $ZYME Contracts: $ZYME April 17, 2026 $18 Calls Scale in: $5.31- $6.48 Scale out: $20.63-$35.37 Profit Potential : 112% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 6:55 PM
Wells Fargo updates rating for Zymeworks ( $ZYME ) to Equal-Weight, target set at 15 → 17.
0 · Reply
Boris_Badenov
Boris_Badenov Nov. 7 at 2:40 PM
$ZYME MOAS mother of all shakeouts in progress imo
1 · Reply